Mays Cancer Center led studies of innovative breast cancer drug that recently gained FDA approval

<p>Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO (Feb. 1, 2023) — The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast [&hellip;]</p>